Last reviewed · How we verify
IMC-002
At a glance
| Generic name | IMC-002 |
|---|---|
| Sponsor | ImmuneOncia Therapeutics Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients (PHASE3)
- A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy (PHASE1)
- A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients (PHASE1, PHASE2)
- A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus (PHASE1, PHASE2)
- A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas (PHASE1)
- Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression (PHASE1)
- A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMC-002 CI brief — competitive landscape report
- IMC-002 updates RSS · CI watch RSS
- ImmuneOncia Therapeutics Inc. portfolio CI